Loading stock data…
CNMD
$35.88-0.92 (-2.50%)
Market ClosedLast close May 4
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CONMED Corporation in the Healthcare sector is trading at $35.88. The stock is currently near its 52-week low of $33.21, remaining 18.5% below its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why CNMD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$35.88
Potential Downside
21%
Whystock Fair Value$28.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$42.00+17.1%
Range$39.00 – $52.00
Fundamentals
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.49
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Strong income play. Yield provides a meaningful total return floor.
209.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.67%
Volume
Today's trading volume
496,007
Recent News
Does CONMED (CNMD) Refocusing Away From Gastroenterology Clarify Its Long-Term Surgical Growth Story?
In late April 2026, CONMED Corporation reported first-quarter sales of US$317.05 million, higher net income of US$13.83 million, and raised its 2026 revenue guidance to US$1.35–US$1.38 billion while confirming a shift away from gastroenterology products. The company’s decision to fully exit gastroenterology and pursue targeted acquisitions underscores a sharper focus on higher-growth orthopedic and minimally invasive surgery platforms supported by a strengthening balance sheet. We’ll now...
Assessing CONMED (CNMD) Valuation After A Mixed Stretch In Recent Share Performance
How CONMED Stock Has Been Trading Recently CONMED (CNMD) has drawn attention after a mixed stretch in the share price, with a slight gain over the past month alongside declines over the past 3 months and year to date. See our latest analysis for CONMED. At a share price of $36.80, CONMED’s recent 30 day share price return of 5.78% contrasts with a weaker 90 day share price return of a 5.13% decline and a 1 year total shareholder return of a 34.92% decline, suggesting momentum has been fading...
Is CONMED Corporation (CNMD) A Good Stock To Buy Now?
Is CNMD a good stock to buy? We came across a bullish thesis on CONMED Corporation on Valueinvestorsclub.com by anton613. In this article, we will summarize the bulls’ thesis on CNMD. CONMED Corporation’s share was trading at $36.79 as of April 28th. CNMD’s trailing P/E was 25.08 according to Yahoo Finance. Conmed Corporation (CNMD) is a medical […]
CNMD Q1 Deep Dive: GI Exit Refocuses Growth on Core Surgical Platforms
Medical tech company CONMED (NYSE:CNMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $317 million. The company expects the full year’s revenue to be around $1.36 billion, close to analysts’ estimates. Its non-GAAP profit of $0.89 per share was 8.8% above analysts’ consensus estimates.
CONMED Corporation Q1 2026 Earnings Call Summary
Moby summary of CONMED Corporation's Q1 2026 earnings call